ST中珠:预计2025年亏损1亿元-1.5亿元

Core Viewpoint - Company ST Zhongzhu (600568) expects a net loss attributable to shareholders of 1 billion to 1.5 billion yuan for the year 2025, an improvement from a loss of 6.2 billion yuan in the previous year [4] Financial Performance - The forecasted net profit loss for 2025 is between 1 billion and 1.5 billion yuan, while the non-recurring net profit loss is expected to be between 1.1 billion and 1.6 billion yuan, compared to a loss of 6.24 billion yuan in the previous year [4] - Historical net profit and non-recurring net profit figures show a consistent decline, with the company reporting a net loss of 6.2 billion yuan in 2023 and 7.99 billion yuan in 2022 [15] - The company's price-to-book ratio (LF) is approximately 3.16 times, and the price-to-sales ratio (TTM) is about 9.5 times based on the latest closing price [4] Business Operations - The company's main business areas include pharmaceutical manufacturing, medical services, medical devices, and real estate [14] - The decline in performance is attributed to the impact of the real estate market environment, leading to a decrease in property prices and significant asset impairment losses from commercial assets [14] - The Beijing Loyal Oncology Hospital project has incurred losses due to its inability to operate normally, and the company is currently executing a court ruling for its vacating [14]